BioXcel Therapeutics Inc (NASDAQ:BTAI) has a beta value of -0.00 and has seen 1.96 million shares traded in the recent trading session. The company, currently valued at $26.04M, closed the recent trade at $0.50 per share which meant it gained $0.09 on the day or 19.98% during that session. The BTAI stock price is -734.0% off its 52-week high price of $4.17 and 40.0% above the 52-week low of $0.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.96 million shares traded. The 3-month trading volume is 668.81K shares.
The consensus among analysts is that BioXcel Therapeutics Inc (BTAI) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.37.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Sporting 19.98% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the BTAI stock price touched $0.50 or saw a rise of 8.49%. Year-to-date, BioXcel Therapeutics Inc shares have moved 32.84%, while the 5-day performance has seen it change 26.13%. Over the past 30 days, the shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) have changed 23.50%. Short interest in the company has seen 0.35 million shares shorted with days to cover at 0.93.
Wall Street analysts have a consensus price target for the stock at $1, which means that the shares’ value could jump 50.0% from the levels at last check today. The projected low price target is $1.0 while the price target rests at a high of $1.0. In that case, then, we find that the latest price level in today’s session is -100.0% off the targeted high while a plunge would see the stock gain -100.0% from the levels at last check today.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
Figures show that BioXcel Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -54.01% over the past 6 months, with this year growth rate of 70.73%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 137.98%.
5 analysts offering their estimates for the company have set an average revenue estimate of 962.12k for the current quarter. 1 have an estimated revenue figure of 400k for the next ending quarter. Year-ago sales stood 376k and 582k respectively for this quarter and the next, and analysts expect sales will grow by 155.88% for the current quarter and 137.98% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -35.97% over the past 5 years.
BTAI Dividends
BioXcel Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
Insiders own 20.06% of the company shares, while shares held by institutions stand at 8.76% with a share float percentage of 10.96%. Investors are also buoyed by the number of investors in a company, with BioXcel Therapeutics Inc having a total of 72.0 institutions that hold shares in the company. The top two institutional holders are ARMISTICE CAPITAL, LLC with over 2.99 million shares worth more than $3.82 million. As of 2024-06-30, ARMISTICE CAPITAL, LLC held 9.6767% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 2.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.82 million and represent 7.1439% of shares outstanding.
